Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4570 - ATM role in Prostate Cancer (PrCa) progression and survival


11 Sep 2017


Poster display session


Translational Research;  Prostate Cancer


Ylenia Cendón Flórez


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


Y. Cendón Flórez1, P. Nombela Blanco2, A. Medina3, N. Romero Laorden2, J. Puente4, P.P. López Casas5, A. Gutierrez Pecharromán6, R. Sanchez-Escribano7, L. Magraner2, E. Gallardo Diaz8, N. Lainez9, P. Jiménez Gallego10, R. Lozano Mejorada11, E. Almagro Casado12, R. Luque Caro13, M. Domenech14, A. Hernández Jorge15, E. Castro Marcos1, M.D.P. González-Peramato Gutierrez16, D. Olmos Hidalgo17

Author affiliations

  • 1 Prostate Cancer Unit, CNIO- Spanish National Cancer Center, 28029 - Madrid/ES
  • 2 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, 28029 - Madrid/ES
  • 3 Medical Oncology, Centro Oncológico de Galicia, A Coruña/ES
  • 4 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 5 Clinical Research, CNIO- Spanish National Cancer Center, 28029 - Madrid/ES
  • 6 Pathology Department, Hospital Universitario de Móstoles, 28935 - Móstoles/ES
  • 7 Medical Oncology, Hospital Universitario de Burgos, Burgos/ES
  • 8 Medical Oncology, Hospital de Sabadell Corporacis Parc Tauli, 8208 - Sabadell/ES
  • 9 Medical Oncology, Complejo Hospitalario de Navarra, 31008 - Pamplona/ES
  • 10 Medical Oncology, , Hospital Universitario de Gran Canaria Dr Negrín, 35010 - Las Palmas de Gran Canaria/ES
  • 11 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid/ES
  • 12 Medical Oncology, Hospital Universitario Quirón Salud, Madrid/ES
  • 13 Medical Oncology, HOSPITAL VIRGEN DE LAS NIEVES, Granada/ES
  • 14 Medical Oncology, Hospital Althaia, Manresa/ES
  • 15 Medical Oncology, Onkologikoa, 20014 - Donostia/ES
  • 16 Pathology Department, Hospital La Paz, 28029 - Madrid/ES
  • 17 Prostate Cancer Clinical Cancer Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid/ES


Abstract 4570


Germline and/or somatic aberrations in ATM gene have been recently identified in up to 5% of PrCa cases. It has been also described that mutations in DNA repair genes predispose individuals to more aggressive and lethal phenotypes. For these reasons, our goal is to investigate the role of ATM in PrCa progression.


To study the cooperation of Atm in prostate cancer progression in vivo, we crossed the transgenic mouse model TRAMP with Atm null mice in C57BL/6 background. This model allows us to elucidate the progression of prostate cancer in wild-type (+/+), heterozygous (+/-), and homozygous (-/-) Atm loss in mice. PIN, invasive and metastatic prostate cancer as well as survival curves were compared for the three arms. In addition, in a large cohort of mCRPC (n = 419) from the prospective PROREPAIR-B study (NCT03075735), in which a large panel of germline DNA repair genes were studied, we compared the clinico-pathological characteristics at baseline and mCRPC diagnosis between germline ATM mutation carriers and non-ATM carriers. Chi-Square and Exact Fisher test, the Kaplan-Meier method and Long-rank test were used for statistical analyses.


Twenty eight TRAMP(T/+); Atm(+/+) and 45 TRAMP(T/+); Atm(+/-) mice were follow-up until sacrifice-endpoint. Heterozygous Atm loss mice presented higher frequency of metastasis in the necropsy compared to Atm wild-type (44% vs. 21%, p = 0,045) and shorter median survival (26 vs. 32 weeks, p = 0,008). There were not significant different observed in PIN or invasive tumour prevalence. TRAMP(T/+); Atm(-/-) mice were excluded from analyses due to the early development of lethal thymomas requiring sacrifice before week 16. On the other hand, 8 patients out of 419 were found to harbour germline pathogenic ATM mutations (1.9%), and compared with non-ATM carriers presented higher frequency stage IV at diagnosis (63% vs. 34%, p = 0.2), bone metastasis (100% vs. 82%, p = 0.4) without other relevant differences found in these preliminary analyses.


Aberration in the ATM gene may favour metastatic progression in PrCa in prostate cancer preclinical models, although its clinical implication will require further clarification in the future.

Clinical trial identification

Part of the results came from the prospective PROREPAIR-B study (NCT03075735)

Legal entity responsible for the study

Spanish National Cancer Research Centre


Prostate Cancer Unit-Spanish National Cancer Research Centre


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.